Welcome to our dedicated page for SERA PROGNOSTICS SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Sera Prognostics Chief Commercial Officer Dyaarl Lee Anderson Jr. received significant equity compensation on June 23, 2025, consisting of two components:
- 67,114 Restricted Stock Units (RSUs) with a four-year vesting schedule: - 25% vests on June 10, 2026 - Remaining 75% vests quarterly over three years
- 102,534 Stock Options with strike price of $1.87: - 25% vests on June 10, 2026 - Remaining 75% vests monthly over three years
Both grants require continued service with the company. The equity awards suggest a long-term retention strategy for the Chief Commercial Officer position, with zero-cost RSUs balanced against performance-based stock options. The relatively low strike price of $1.87 indicates potential upside opportunity in the company's growth prospects.